CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

This study is testing CPI-0209 (an EZH2 inhibitor, a drug that targets a gene-silencing protein in cancer cells) in combination with carboplatin chemotherapy for women with platinum-sensitive recurrent ovarian, fallopian tube, or peritoneal cancer. **You may be eligible if...** - You have ovarian, fallopian tube, or primary peritoneal cancer that has come back - Your cancer is "platinum-sensitive" — meaning it came back more than 6 months after your last platinum-based chemotherapy - You are eligible to receive platinum-based chemotherapy again - You have measurable disease on imaging or documented disease progression **You may NOT be eligible if...** - Your cancer came back within 6 months of platinum chemotherapy (platinum-resistant) - You have received too many prior lines of chemotherapy - You have active brain metastases - You have serious heart, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.